Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the pancreas.

Alliance A021501 is the first randomized trial to evaluate stereotactic body radiation therapy (SBRT) for borderline resectable pancreatic ductal adenocarcinoma (PDAC) after neoadjuvant chemotherapy. In this post hoc study, we reviewed the quality of radiation therapy (RT) delivered.

Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: Leila T. Tchelebi, Diana Segovia, Koren Smith, Qian Shi, TJ Fitzgerald, Michael D. Chuong, Tyler J. Zemla, Eileen M. O'Reilly, Jeffrey Meyerhardt, Eugene J. Koay, Jessica Leif, Ardaman Shergill, Matthew HG Katz, Joseph M. Herman Tags: Clinical Investigation Source Type: research